SR907: SR907 Department of Insurance; to meet with stakeholders to explore best practices in the medical surveillance of patients after primary therapy for breast cancer and to provide any recommendations; urge

26 LC 52 1066 Senate Resolution 907 By: Senators Williams of the 25th, Burns of the 23rd, Hickman of the 4th, Goodman of the 8th, Kirkpatrick of the 32nd, and others A RESOLUTION Urging the Department of Insurance, in collaboration with the D epartment of Community1 Health, to meet with stakeholders to explore best practices in the medical surveillance of2 patients after primary therapy for breast cancer and to provide any recommendations; and for3 other purposes.4 WHEREAS, breast cancer is the second most common cancer diagnos ed in women in the5 United States and the second leading cause of death from cancer among women in the United6 States; and7 WHEREAS, the American Cancer Society estimates that, in 2026, about 2,670 men will be8 diagnosed with invasive breast cancer and about 530 men will die from breast cancer; and9 WHEREAS, depending on the individual patient and the type and s tage of breast cancer,10 treatments for breast cancer include surgery, such as a lumpect omy, breast-conserving11 surgery, mastectomy, or double mastectomy, and adjuvant therapy, such as chemotherapy,12 radiotherapy, hormone therapy, targeted therapy, or biological therapy; and13 WHEREAS, after treatments for breast cancer, medical surveillance is crucial to monitor and14 detect any local recurrence of cancer in either breast, the bre ast area, the chest wall, or15 S. R. 907 - 1 - 26 LC 52 1066 regional lymph nodes and to monitor and detect distant metastas es or therapy related16 diseases; and 17 WHEREAS, there is debate on the cost-effectiveness, accuracy, a nd medical necessity of18 routine mammography, X-rays, ultrasounds, magnetic resonance imaging, positron emission19 tomography scans, and computed tomography scans after a mastect omy or double20 mastectomy when the patient is asymptomatic; and21 WHEREAS, a well-defined, evidence based surveillance protocol i s needed to manage22 patients with breast cancer after the initial diagnosis, during staging, after primary treatment,23 and during any follow-up care to detect early local recurrence of cancer and distant24 metastases or therapy related diseases; and25 WHEREAS, the Department of Insurance, in collaboration with the Department of26 Community Health, is in the optimal position to gather data and information from27 stakeholders, including, but not limited to, breast cancer survivors; family members of breast28 cancer survivors; medical, surgical, and radiation oncologists; radiologists; pathologists;29 other healthcare providers; and health insurers.30 NOW, THEREFORE, BE IT RESOLVED BY THE SENATE that the members of this body31 urge the Department of Insurance, in collaboration with the Dep artment of Community32 Health, to meet with stakeholders to explore best practices in the medical surveillance of33 patients after primary therapy for breast cancer and to provide any recommendations.34 BE IT FURTHER RESOLVED that the Department of Insurance shall s ubmit any35 recommendations to the chairpersons of the Senate Insurance and Labor Committee and the36 Senate Health and Human Services Committee no later than February 1, 2027, along with37 S. R. 907 - 2 - 26 LC 52 1066 any proposed legisla tion, policy, or budget ch anges needed to i mplement such38 recommendations.39 BE IT FURTHER RESOLVED that the Secretary of the Senate is authorized and directed40 to make appropriate copies of this resolution available for distribution to the Commissioner41 of Insurance and the commissioner of the Department of Community Health.42 S. R. 907 - 3 -